1p/19q loss within oligodendroglioma is predictive for response to first line temozolomide but not to salvage treatment

被引:87
作者
Kouwenhoven, Mathilde C. M.
Kros, Johan M.
French, Pim J.
Biemond-ter Stege, Elize M.
Graveland, Wilfried J.
Taphoorn, Martin J. B.
Brandes, Alba A.
van den Bent, Martin J.
机构
[1] Daniel Den Hoed Oncol Ctr, Dept Neurooncol, NL-3008 AE Rotterdam, Netherlands
[2] Erasmus MC, Dept Pathol, Rotterdam, Netherlands
[3] Daniel Den Hoed Oncol Ctr, Dept Med Stat, NL-3008 AE Rotterdam, Netherlands
[4] MC Haaglanden Westeinde Hosp, Dept Neurol, The Hague, Netherlands
[5] Univ Padua, Azienda Osped, Ist Oncol, Neuroncol Unit,Med Oncol Dept, Padua, Italy
关键词
anaplastic oligodendroglioma; anaplastic oligoastrocytorna; glioma; PCV; temozolomide; chemotherapy; 1p; 19q;
D O I
10.1016/j.ejca.2006.05.021
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Combined loss of 1p/19q predicts an almost 100% response rate to first line procarbazine, CCNU and vincristine chemotherapy (PCV) chemotherapy in oligodendroglial tumours. We assessed the impact of 1p and 19q loss on the outcome to first line temozolomide (TMZ) chemotherapy and to second line PCV or TMZ in progressive oligodendroglial tumours. Materials and methods: Tumour samples from patients included in two prospective EORTC studies on first line and second line TMZ chemotherapy in recurrent oligodendroglioma were used for this study. Most patients in the first line TMZ trial received PCV at further progression. Loss of 1p and 19q was assessed on paraffin embedded tumour samples by fluorescent in situ hybridisation with locus specific probes for 1p36 and 19q13. Results: Losses of 1p and 19q were mainly observed in morphologically classical oligodendrogliomas (OD). Thirteen out of 18 patients with 1p loss (72%) responded to first line temozolomide (p < 0.01). Both response to second line salvage PCV or to second line temozolomide was limited, even in patients with combined 1p/19q loss. Patients with tumours with 1p loss treated with salvage PCV had improved PFS (p < 0.05). More patients with 1p loss were alive at 60 and 120 months after initial surgery (p < 0.001). Conclusion: Combined 1p/19q loss is mainly observed in classical OD. Responses to first line temozolomide are strongly correlated to loss of 1p. Response to second line alkylating treatment is modest even in tumours with 1p/19q loss. For further improvement of outcome in OD novel treatments are needed. (c) 2006 Elsevier Ltd. All rights reserved.
引用
收藏
页码:2499 / 2503
页数:5
相关论文
共 21 条
[1]   Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas [J].
Brada, M ;
Viviers, L ;
Abson, C ;
Hines, F ;
Britton, J ;
Ashley, S ;
Sardell, S ;
Traish, D ;
Gonsalves, A ;
Wilkins, P ;
Westbury, C .
ANNALS OF ONCOLOGY, 2003, 14 (12) :1715-1721
[2]   Temozolomide as a second-line systemic regimen in recurrent high-grade glioma:: A phase II study [J].
Brandes, AA ;
Ermani, M ;
Basso, U ;
Amistà, P ;
Berti, F ;
Scienza, R ;
Rotilio, A ;
Pinna, G ;
Gardiman, M ;
Monfardini, S .
ANNALS OF ONCOLOGY, 2001, 12 (02) :255-257
[3]   CHEMOTHERAPY FOR ANAPLASTIC OLIGODENDROGLIOMA [J].
CAIRNCROSS, G ;
MACDONALD, D ;
LUDWIN, S ;
LEE, D ;
CASCINO, T ;
BUCKNER, J ;
FULTON, D ;
DROPCHO, E ;
STEWART, D ;
SCHOLD, C ;
WAINMAN, N ;
EISENHAUER, E .
JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (10) :2013-2021
[4]   Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas [J].
Cairncross, JG ;
Ueki, K ;
Zlatescu, MC ;
Lisle, DK ;
Finkelstein, DM ;
Hammond, RR ;
Silver, JS ;
Stark, PC ;
Macdonald, DR ;
Ino, Y ;
Ramsay, DA ;
Louis, DN .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (19) :1473-1479
[5]   Impact of chromosome 1p status in response of oligodendroglioma to temozolomide: preliminary results [J].
Chahlavi, A ;
Kanner, A ;
Peereboom, D ;
Staugaitis, SM ;
Elson, P ;
Barnett, G .
JOURNAL OF NEURO-ONCOLOGY, 2003, 61 (03) :267-273
[6]   Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy [J].
Chinot, OL ;
Honore, S ;
Dufour, H ;
Barrie, M ;
Figarella-Branger, D ;
Muracciole, X ;
Braguer, D ;
Martin, PM ;
Grisoli, F .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (09) :2449-2455
[7]  
Coons SW, 1997, CANCER, V79, P1381, DOI 10.1002/(SICI)1097-0142(19970401)79:7<1381::AID-CNCR16>3.0.CO
[8]  
2-W
[9]   Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions [J].
Hoang-Xuan, K ;
Capelle, L ;
Kujas, M ;
Taillibert, S ;
Duffau, H ;
Lejeune, J ;
Polivka, M ;
Crinière, E ;
Marie, Y ;
Mokhtari, K ;
Carpentier, AF ;
Laigle, F ;
Simon, JM ;
Cornu, P ;
Broët, P ;
Sanson, M ;
Delattre, JY .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (15) :3133-3138
[10]   Long survival and therapeutic responses in patients with histologically disparate high-grade gliomas demonstrating chromosome 1p loss [J].
Ino, Y ;
Zlatescu, MC ;
Sasaki, H ;
MacDonald, DR ;
Stemmer-Rachamimov, AO ;
Jhung, S ;
Ramsay, DA ;
von Deimling, A ;
Louis, DN ;
Cairncross, JG .
JOURNAL OF NEUROSURGERY, 2000, 92 (06) :983-990